Charlotte K. Boughton
A5033841981- Diabetes Management and Research
- Pancreatic function and diabetes
- Diabetes and associated disorders
- Diabetes Treatment and Management
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Diabetes Management and Education
- Regulation of Appetite and Obesity
- Neuropeptides and Animal Physiology
- Sleep and related disorders
- Chronic Disease Management Strategies
- Cardiac pacing and defibrillation studies
- Adolescent and Pediatric Healthcare
- Cardiovascular Function and Risk Factors
- Neuroendocrine regulation and behavior
- Pharmaceutical studies and practices
- Mobile Health and mHealth Applications
- Diet and metabolism studies
- Electrolyte and hormonal disorders
- Hormonal Regulation and Hypertension
- Health Systems, Economic Evaluations, Quality of Life
- Stress Responses and Cortisol
- Childhood Cancer Survivors' Quality of Life
- Potassium and Related Disorders
- Health and Lifestyle Studies
- Obesity, Physical Activity, Diet
University of Cambridge
2018-2025
Wellcome/MRC Institute of Metabolic Science
2018-2024
Cambridge University Hospitals NHS Foundation Trust
2019-2024
Wellcome Trust
2018-2024
Medical Research Council
2018-2024
Addenbrooke's Hospital
2019-2024
National Health Service
2024
Centre Hospitalier de Luxembourg
2022
University of Oxford
2022
Cambridge School
2021
Abstract The significant and growing global prevalence of diabetes continues to challenge people with (PwD), healthcare providers, payers. While maintaining near-normal glucose levels has been shown prevent or delay the progression long-term complications diabetes, a proportion PwD are not attaining their glycemic goals. During past 6 years, we have seen tremendous advances in automated insulin delivery (AID) technologies. Numerous randomized controlled trials real-world studies that use AID...
The possible advantage of hybrid closed-loop therapy (i.e., artificial pancreas) over sensor-augmented pump in very young children with type 1 diabetes is unclear.In this multicenter, randomized, crossover trial, we recruited to 7 years age who were receiving insulin-pump at seven centers across Austria, Germany, Luxembourg, and the United Kingdom. Participants received treatment two 16-week periods, random order, which system was compared (control). primary end point between-treatment...
Whether improved glucose control with hybrid closed-loop therapy can preserve C-peptide secretion as compared standard insulin in persons new-onset type 1 diabetes is unclear.In a multicenter, open-label, parallel-group, randomized trial, we assigned youths 10.0 to 16.9 years of age within 21 days after diagnosis receive or (control) for 24 months. The primary end point was the area under curve (AUC) plasma level (after mixed-meal tolerance test) at 12 months diagnosis. analysis performed on...
In adults with type 2 diabetes, the benefits of fully closed-loop insulin delivery, which does not require meal bolusing, are unclear. an open-label, single-center, randomized crossover study, 26 diabetes (7 women and 19 men; (mean ± s.d.) age, 59 11 years; baseline glycated hemoglobin (HbA1c), 75 15 mmol mol-1 (9.0% 1.4%)) underwent two 8-week periods to compare CamAPS HX app standard therapy a masked glucose sensor (control) in random order, 2-week 4-week washout between periods. The...
OBJECTIVE We aimed to assess the feasibility and safety of hybrid closed-loop insulin delivery in children with type 1 diabetes aged 1–7 years as well evaluate role diluted on glucose control. RESEARCH DESIGN AND METHODS In an open-label, multicenter, multinational, randomized crossover study, 24 pump therapy (median age 5 [interquartile range 3–6] mean ± SD HbA1c 7.4 0.7% [57 8 mmol/mol] total 13.2 4.8 units/day) underwent two 21-day periods unrestricted living we compared (U20) standard...
Objective To evaluate the experiences of families with very young children aged 1 to 7 years (inclusive) type diabetes using day-and-night hybrid closed-loop insulin delivery. Methods Parents/caregivers 20 completed a experience survey following two 3-week periods unrestricted therapy Cambridge FlorenceM system at home. Benefits, limitations, and improvements technology were explored. Results Responders reported reduced burden management, less time spent managing diabetes, improved quality...
Glucose management is challenging in patients who require nutritional support hospital. We aimed to assess whether fully closed-loop insulin delivery would improve glycaemic control compared with conventional subcutaneous therapy inpatients receiving enteral or parenteral nutrition both.
Abstract We evaluated the safety and efficacy of fully closed-loop insulin therapy compared with standard in adults type 2 diabetes requiring dialysis. In an open-label, multinational, two-center, randomized crossover trial, 26 dialysis (17 men, 9 women, average age 68 ± 11 years (mean s.d.), duration 20 10 years) underwent two 20-day periods unrestricted living, comparing Cambridge system using faster aspart (‘closed-loop’) a masked continuous glucose monitor (‘control’) random order. The...
To evaluate the use of hybrid closed-loop glucose control with faster-acting insulin aspart (Fiasp) in adults type 1 diabetes (T1D).
Closed-loop insulin delivery systems have the potential to address suboptimal glucose control in children and adolescents with type 1 diabetes. We compared safety efficacy of Cambridge hybrid closed-loop algorithm usual care over 6 months this population.
OBJECTIVE To quantify age-related variability of insulin needs during day and night closed-loop delivery. RESEARCH DESIGN AND METHODS We retrospectively analyzed data from hybrid studies involving young children (1–6 years old, n = 20), (7–12 years, 21), adolescents (13–17 15), adults (>18 58) with type 1 diabetes. The coefficient variation quantified 3 weeks unrestricted-living use. RESULTS Data 2,365 nights 2,367 days in 114 participants were analyzed. delivery was higher compared...
We evaluated the safety and efficacy of fully closed-loop with ultrarapid insulin lispro in adults type 1 diabetes suboptimal glycemic control compared pump therapy continuous glucose monitoring (CGM).This single-center, randomized, crossover study enrolled 26 using (mean ± SD, age 41 12 years, HbA1c 9.2 1.1% [77 mmol/mol]). Participants underwent two 8-week periods unrestricted living to compare (CamAPS HX system) CGM random order.In an intention-to-treat analysis, proportion time was range...
Abstract Aim To explore health professionals' views about who would benefit from using a closed‐loop system and should be prioritized for access to the technology in routine clinical care. Methods Health professionals (n = 22) delivering Closed Loop Onset type 1 Diabetes (CLOuD) trial were interviewed after they had ≥ 6 months' experience supporting participants system. Data analysed thematically. Results Interviewees described holding strong assumptions types of people use effectively prior...
We evaluated the use of hybrid closed-loop (HCL) insulin delivery with faster aspart (Fiasp) in very young children type 1 diabetes (T1D). In a double-blind, multicenter, randomized, crossover study, aged 2–6 years T1D underwent two 8-week periods HCL using CamAPS FX Fiasp and standard (IAsp), random order. Primary endpoint was between-treatment difference time target range 3.9–10.0 mmol/L. randomized 25 participants: mean (±standard deviation) age 5.1 ± 1.3 years, baseline HbA1c 55 9...
Introduction: To evaluate hybrid closed-loop with ultra-rapid insulin lispro (Lyumjev) compared standard in adults type 1 diabetes. Materials and Methods: In a single-center, double-blind, randomized, crossover study, 28 diabetes (mean ± deviation [SD]: age 44.5 10.7 years, glycated hemoglobin (HbA1c) 7.1 0.9% [54 10 mmol/mol]) underwent two 8-week periods comparing random order. The same CamAPS FX algorithm was used both periods. Results: an intention-to-treat analysis, the proportion of...
Objective: To evaluate postprandial glucose control when applying (1) faster-acting insulin aspart (Fiasp) compared to and (2) ultra-rapid lispro (Lyumjev) using the CamAPS FX hybrid closed-loop algorithm.
We evaluated the effect of long-term intensive metabolic control with hybrid closed-loop (CL) on residual C-peptide secretion and glucose compared standard insulin therapy in youth type 1 diabetes over 48 months.